Nabil Adra

19PUBLICATIONS
134CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanomedicinePharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|May 14, 2026
How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.

|Feb 18, 2026
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr

|Sep 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Rebecca Hassoun, Reuben Ben-David, John P Sfakianos

|Mar 27, 2025
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma.

Roberto Pili, David I Quinn, Nabil Adra

|Feb 06, 2025
Prediction Model for Brain Metastasis in Patients With Metastatic Germ-Cell Tumors.

Tareq Salous, Ryan Ashkar, Sandra K Althouse

|Oct 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.

Young Kwang Chae, Megan Othus, Sandip Pravin Patel

Pageof 4

Frequent Collaborators

5 joint publications

Clint Cary

3 joint publications

Isamu Tachibana

2 joint publications

Siamak Daneshmand

2 joint publications

Tanya Dorff